Sawai’s Japan Core Profit Tumbles 39% As Upsher-Smith Continues Revival
Company Seeing Fewer Limits On Shipments But Still Facing Japan Headwinds
Executive Summary
Sawai’s Q1 momentum spread into its overall first half financial results, with setbacks and risks in its dominant Japanese business and greener shoots for its formerly spluttering Upsher-Smith operation in the US.
You may also be interested in...
Tough Times Ahead For Towa As Japanese Generics Giant Slashes 2023 Predictions
Towa has made substantial cuts to its 2023 financial guidance as the difficult conditions of the Japanese generics market begin to take their toll.
Sawai’s Upsher-Smith Gets New Leadership Amid ‘Drastic Restructuring’
A major overhaul is in progress for Sawai’s Upsher-Smith business, after the Japanese parent company announced leadership changes and a “drastic restructuring” of the US unit in the wake of a significant impairment charge and a hefty annual operating loss that dragged down Sawai’s overall results.
Too Fast, Too Much? Japan Cuts Prices By 6.7% As Annual Revisions Bite
The Japanese government will apply new drug reimbursement prices from 1 April, under which Pfizer’s Vyndaqel will be slashed by 75% and UCB's E Keppra by 26%. Nobelpharma and Santen will be also affected by the revision, which averages close to 7% across the board.